Literature DB >> 2418066

Modulation of insulinlike growth factor I binding to human fibroblast monolayer cultures by insulinlike growth factor carrier proteins released to the incubation media.

M A De Vroede, L Y Tseng, P G Katsoyannis, S P Nissley, M M Rechler.   

Abstract

The relative contributions of type I and type II insulinlike growth factor (IGF) receptors and IGF carrier proteins to the binding of IGF-I tracer to cultured human fibroblasts were determined in competitive binding experiments that used unlabeled insulin and synthetic insulin-IGF-I hybrid molecules containing the A chain of insulin and the B domain of IGF-I. Whereas insulin binds only to type I IGF receptors, the B-IGF-I hybrids bind to type I receptors and IGF carrier proteins but not to type II receptors. In suspended human fibroblasts, IGF-I tracer binds predominantly to type I IGF receptors (inhibition by IGF-I much greater than insulin greater than B-IGF-I hybrid molecules). By contrast, in fibroblast monolayers, IGF-I binding was minimally inhibited by insulin or hybrid molecules, suggesting predominant binding to the type II IGF receptor. The type I receptor appears to be masked on fibroblast monolayers, and to require suspension or detergent solubilization of the cells to be demonstrated. In the course of the monolayers binding experiments, we noted that low concentrations of unlabeled IGF-I (5-10 ng/ml) or B-IGF-I hybrids (100 ng/ml) paradoxically increased IGF-I tracer binding up to twofold. We postulated that during the binding incubation (5 h, 15 degrees C), IGF-I tracer partitioned between binding sites on the cell surface and IGF carrier proteins released to the incubation media. Preferential occupancy of binding sites in the media by unlabeled ligand increased the tracer available to bind to the cells. In support of this hypothesis, carrier proteins were demonstrated in the media at the end of the binding incubation with fibroblast monolayers, and the concentration of unsaturated binding sites in the media correlated inversely with tracer binding to the cells. Thus carrier proteins released to the media during the binding incubation modulate the binding of IGF-I tracer to cell receptors, suggesting that the carrier proteins may play an important role in regulating cellular responsiveness to the IGFs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418066      PMCID: PMC423394          DOI: 10.1172/JCI112343

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  DNA synthesis in human fibroblasts: stimulation by insulin and by nonsuppressible insulin-like activity (NSILA-S).

Authors:  M M Rechler; J M Podskalny; I D Goldfine; C A Wells
Journal:  J Clin Endocrinol Metab       Date:  1974-09       Impact factor: 5.958

2.  Isolation of the insulin receptor of liver and fat-cell membranes (detergent-solubilized-( 125 I)insulin-polyethylene glycol precipitation-sephadex).

Authors:  P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

3.  Interactions of insulin-like growth factors I and II and multiplication-stimulating activity with receptors and serum carrier proteins.

Authors:  M M Rechler; J Zapf; S P Nissley; E R Froesch; A C Moses; J M Podskalny; E E Schilling; R E Humbel
Journal:  Endocrinology       Date:  1980-11       Impact factor: 4.736

4.  Demonstration of two subtypes of insulin-like growth factor receptors by affinity cross-linking.

Authors:  M Kasuga; E Van Obberghen; S P Nissley; M M Rechler
Journal:  J Biol Chem       Date:  1981-06-10       Impact factor: 5.157

5.  Identification of a receptor for somatomedin-like polypeptides in human fibroblasts.

Authors:  M M Rechler; S P Nissley; J M Podskalny; A C Moses; L Fryklund
Journal:  J Clin Endocrinol Metab       Date:  1977-05       Impact factor: 5.958

6.  Further characterization of growth hormone-dependent somatomedin-binding proteins in rat serum and demonstration of somatomedin-binding proteins produced by rat liver cells in culture.

Authors:  A C Moses; S P Nissley; J Passamani; R M White
Journal:  Endocrinology       Date:  1979-02       Impact factor: 4.736

7.  Stimulation of glucose incorporation and amino acid transport by insulin and an insulin-like growth factor in fibroblasts with defective insulin receptors cultured from a patient with leprechaunism.

Authors:  A B Knight; M M Rechler; J A Romanus; E E Van Obberghen-Schilling; S P Nissley
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

8.  Receptors for insulinlike growth factor I are defective in fibroblasts cultured from a patient with leprechaunism.

Authors:  E E Van Obberghen-Schilling; M M Rechler; J A Romanus; A B Knight; S P Nissley; R E Humbel
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

9.  Direct demonstration of separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulinlike growth factor) using antibodies to the insulin receptor.

Authors:  G L King; C R Kahn; M M Rechler; S P Nissley
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

10.  Hormonal control of immunoreactive somatomedin production by cultured human fibroblasts.

Authors:  D R Clemmons; L E Underwood; J J Van Wyk
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

View more
  19 in total

1.  Granulosa cell-derived insulin-like growth factor (IGF) binding proteins are inhibitory to IGF-I hormonal action. Evidence derived from the use of a truncated IGF-I analogue.

Authors:  E Y Adashi; C E Resnick; E Ricciarelli; A Hurwitz; E Kokia; C Tedeschi; L Botero; E R Hernandez; R G Rosenfeld; C Carlsson-Skwirut
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

2.  Mitogenic effects of growth hormone in cultured human fibroblasts. Evidence for action via local insulin-like growth factor I production.

Authors:  J J Cook; K M Haynes; G A Werther
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

Review 3.  Somatomedin-binding proteins: what role do they play in the growth process?

Authors:  S Cianfarani; J M Holly
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

4.  Specific binding of insulin-like growth factors 1 and 2 to the type 1 and type 2 receptors respectively.

Authors:  F J Ballard; M Ross; F M Upton; G L Francis
Journal:  Biochem J       Date:  1988-02-01       Impact factor: 3.857

5.  Differential modulation of mitogenic and metabolic actions of insulin-like growth factor I in rat glomerular mesangial cells in high glucose culture.

Authors:  R Kikkawa; M Haneda; M Togawa; D Koya; N Kajiwara; Y Shigeta
Journal:  Diabetologia       Date:  1993-04       Impact factor: 10.122

6.  A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide.

Authors:  C J Bagley; B L May; L Szabo; P J McNamara; M Ross; G L Francis; F J Ballard; J C Wallace
Journal:  Biochem J       Date:  1989-05-01       Impact factor: 3.857

7.  Increased activity of the insulin-like growth factor system in mesangial cells cultured in high glucose conditions. Relation to glucose-enhanced extracellular matrix production.

Authors:  G Pugliese; F Pricci; N Locuratolo; G Romeo; G Romano; S Giannini; B Cresci; G Galli; C M Rotella; U Di Mario
Journal:  Diabetologia       Date:  1996-07       Impact factor: 10.122

8.  The role of insulin-like growth factor-1 (IGF-1) in follicular thyroid cancer cell line CGTH W-1.

Authors:  J D Lin; Y S Ho; H Y Chang; H F Weng
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-12       Impact factor: 2.416

9.  Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells.

Authors:  J Hofmann; B Wegmann; R Hackenberg; R Kunzmann; K D Schulz; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats.

Authors:  A Flyvbjerg; U Kessler; B Dorka; B Funk; H Orskov; W Kiess
Journal:  Diabetologia       Date:  1992-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.